HC Wainwright & Co. Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Longboard Pharmaceuticals and raised the price target from $60 to $80, indicating confidence in the company's future performance.
September 18, 2024 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has increased its price target for Longboard Pharmaceuticals from $60 to $80, maintaining a Buy rating. This suggests a positive outlook and potential for stock price appreciation.
The increase in price target from $60 to $80 by HC Wainwright & Co. reflects a strong positive sentiment towards Longboard Pharmaceuticals. Maintaining a Buy rating suggests confidence in the company's future performance, likely leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100